Ronald Hoffman

22.2k total citations · 2 hit papers
364 papers, 12.2k citations indexed

About

Ronald Hoffman is a scholar working on Genetics, Hematology and Molecular Biology. According to data from OpenAlex, Ronald Hoffman has authored 364 papers receiving a total of 12.2k indexed citations (citations by other indexed papers that have themselves been cited), including 232 papers in Genetics, 207 papers in Hematology and 98 papers in Molecular Biology. Recurrent topics in Ronald Hoffman's work include Myeloproliferative Neoplasms: Diagnosis and Treatment (203 papers), Acute Myeloid Leukemia Research (99 papers) and Chronic Myeloid Leukemia Treatments (92 papers). Ronald Hoffman is often cited by papers focused on Myeloproliferative Neoplasms: Diagnosis and Treatment (203 papers), Acute Myeloid Leukemia Research (99 papers) and Chronic Myeloid Leukemia Treatments (92 papers). Ronald Hoffman collaborates with scholars based in United States, Italy and Canada. Ronald Hoffman's co-authors include John Mascarenhas, Amelia Bartholomew, Cord Sturgeon, Sheila Patil, Karen Ferrer, Robert Deans, Annemarie Moseley, Ruben A. Mesa, Steve Devine and David S. Ucker and has published in prestigious journals such as Science, New England Journal of Medicine and The Lancet.

In The Last Decade

Ronald Hoffman

339 papers receiving 11.8k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo

2002 1.8k citations Ronald Hoffman et al. profile →
Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel

2007 604 citations Ayalew Tefferi, Jüergen Thiele et al. Blood profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Ronald Hoffman	7.4k	5.4k	5.0k	2.1k	1.5k	364	12.2k
Rhett P. Ketterling	7.0k 0.9×	9.1k 1.7×	6.6k 1.3×	2.5k 1.2×	1.1k 0.7×	402	14.4k
D. Gary Gilliland	4.2k 0.6×	8.1k 1.5×	8.4k 1.7×	2.0k 1.0×	2.1k 1.4×	126	16.2k
Nora Heisterkamp	4.9k 0.7×	7.4k 1.4×	6.7k 1.3×	1.9k 0.9×	1.5k 1.0×	220	15.2k
Gordon W. Dewald	5.2k 0.7×	7.7k 1.4×	4.4k 0.9×	1.2k 0.6×	1.8k 1.2×	212	13.1k
Nicholas C.P. Cross	8.5k 1.2×	11.5k 2.1×	7.1k 1.4×	6.4k 3.1×	2.6k 1.8×	395	19.9k
Annelies de Klein	2.5k 0.3×	3.3k 0.6×	5.2k 1.0×	911 0.4×	1.2k 0.8×	219	11.5k
Tim H. Brümmendorf	3.4k 0.5×	4.3k 0.8×	2.9k 0.6×	1.7k 0.8×	1.1k 0.8×	298	9.0k
D. Gary Gilliland	9.6k 1.3×	12.2k 2.2×	12.2k 2.5×	4.0k 1.9×	2.6k 1.8×	144	22.5k
Catriona Jamieson	2.9k 0.4×	3.4k 0.6×	6.7k 1.3×	822 0.4×	1.9k 1.3×	187	12.2k
Susanne Schnittger	6.2k 0.8×	13.1k 2.4×	7.7k 1.5×	964 0.5×	1.8k 1.2×	435	17.5k

Countries citing papers authored by Ronald Hoffman

Since Specialization

Citations

This map shows the geographic impact of Ronald Hoffman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ronald Hoffman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ronald Hoffman more than expected).

Fields of papers citing papers by Ronald Hoffman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ronald Hoffman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ronald Hoffman. The network helps show where Ronald Hoffman may publish in the future.

Co-authorship network of co-authors of Ronald Hoffman

This figure shows the co-authorship network connecting the top 25 collaborators of Ronald Hoffman. A scholar is included among the top collaborators of Ronald Hoffman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ronald Hoffman. Ronald Hoffman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Lü, Min, Lijuan Xia, & Ronald Hoffman. (2023). Use of Combination Therapies Including the XPO1 Inhibitor Selinexor in Is a Potential Effective Therapeutic Strategy to Treat Myelofibrosis Patients. Blood. 142(Supplement 1). 1792–1792. 1 indexed citations

Saleiro, Diana, Ewa M. Kościuczuk, Mariafausta Fischietti, et al.. (2023). Targeting CHAF1B Enhances IFN Activity against Myeloproliferative Neoplasm Cells. Cancer Research Communications. 3(5). 943–951. 3 indexed citations

Melo‐Cardenas, Johanna, Jeremy Chase Crawford, Sandeep Gurbuxani, et al.. (2022). IL-13/IL-4 signaling contributes to fibrotic progression of the myeloproliferative neoplasms. Blood. 140(26). 2805–2817. 35 indexed citations

Saleiro, Diana, Ewa M. Kościuczuk, Frank Eckerdt, et al.. (2022). Discovery of a signaling feedback circuit that defines interferon responses in myeloproliferative neoplasms. Nature Communications. 13(1). 1750–1750. 15 indexed citations

Mascarenhas, John, Hélène F.E. Gleitz, Helen T. Chifotides, et al.. (2022). Biological drivers of clinical phenotype in myelofibrosis. Leukemia. 37(2). 255–264. 28 indexed citations

Varricchio, Lilian, Camelia Iancu‐Rubin, Bhaskar Upadhyaya, et al.. (2021). TGF-β1 protein trap AVID200 beneficially affects hematopoiesis and bone marrow fibrosis in myelofibrosis. JCI Insight. 6(18). 39 indexed citations

Tremblay, Douglas, Lukas Ronner, Nikolai A. Podoltsev, et al.. (2021). Ruxolitinib discontinuation in polycythemia vera: Patient characteristics, outcomes, and salvage strategies from a large multi-institutional database. Leukemia Research. 109. 106629–106629. 2 indexed citations

Bozkus, Cansu Cimen, Vladimir Roudko, John P. Finnigan, et al.. (2019). Immune Checkpoint Blockade Enhances Shared Neoantigen-Induced T-cell Immunity Directed against Mutated Calreticulin in Myeloproliferative Neoplasms. Cancer Discovery. 9(9). 1192–1207. 69 indexed citations

Marcellino, Bridget K., Ronald Hoffman, Joseph Tripodi, et al.. (2018). Advanced forms of MPNs are accompanied by chromosomal abnormalities that lead to dysregulation of TP53. Blood Advances. 2(24). 3581–3589. 46 indexed citations

10.

Papa, Luena, Eran Zimran, Mansour Djedaini, et al.. (2018). Ex vivo human HSC expansion requires coordination of cellular reprogramming with mitochondrial remodeling and p53 activation. Blood Advances. 2(20). 2766–2779. 32 indexed citations

11.

Chen, Yaoyu, Yi Shan, Min Lü, et al.. (2016). Alox5 Blockade Eradicates JAK2V617F -Induced Polycythemia Vera in Mice. Cancer Research. 77(1). 164–174. 10 indexed citations

12.

Xu, Mingjiang, et al.. (2010). The Effect of CXCL12 Processing on CD34+ Cell Migration in Myeloproliferative Neoplasms. Cancer Research. 70(8). 3402–3410. 55 indexed citations

13.

Lü, Min, Jiapeng Wang, Yan Li, et al.. (2010). Treatment with the Bcl-xL inhibitor ABT-737 in combination with interferon α specifically targets JAK2V617F-positive polycythemia vera hematopoietic progenitor cells. Blood. 116(20). 4284–4287. 22 indexed citations

14.

Wang, Xiaoli, Wei Zhang, Takefumi Ishii, et al.. (2009). Correction of the Abnormal Trafficking of Primary Myelofibrosis CD34+ Cells by Treatment with Chromatin-Modifying Agents. Cancer Research. 69(19). 7612–7618. 30 indexed citations

15.

Sözer, Selçuk, Maria Isabel Fiel, Thomas D. Schiano, et al.. (2009). The presence of JAK2V617F mutation in the liver endothelial cells of patients with Budd-Chiari syndrome. Blood. 113(21). 5246–5249. 134 indexed citations

16.

Ishii, Takefumi, Jiapeng Wang, Wei Zhang, et al.. (2009). Pivotal role of mast cells in pruritogenesis in patients with myeloproliferative disorders. Blood. 113(23). 5942–5950. 67 indexed citations

17.

Seaman, Vincent, Aisha O. Jumaan, Emad Yanni, et al.. (2009). Use of Molecular Testing to Identify a Cluster of Patients with Polycythemia Vera in Eastern Pennsylvania. Cancer Epidemiology Biomarkers & Prevention. 18(2). 534–540. 13 indexed citations

18.

Tefferi, Ayalew, Jüergen Thiele, Attilio Orazi, et al.. (2007). Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood. 110(4). 1092–1097. 604 indexed citations breakdown →

19.

Hoffman, Ronald & Mingjiang Xu. (2006). Is bone marrow fibrosis the real problem?. Blood. 107(9). 3421–3422. 4 indexed citations

20.

Srour, Edward F., Ronald Hoffman, & Esmail D. Zanjani. (1992). Animal Models for Human Hematopoiesis. Journal of Hematotherapy. 1(2). 143–153. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact